Today's noteworthy downgrades include: Apple Hospitality REIT (APLE) downgraded to Sell from Neutral at Ladenburg... Arch Capital (ACGL) downgraded to Neutral from Outperform at Macquarie... Atmel (ATML) downgraded to Equal Weight from Overweight at Morgan Stanley... BAE Systems (BAESY) downgraded to Underperform from Neutral at Credit Suisse... Bed Bath & Beyond (BBBY) downgraded to Underweight from Hold at BB&T... Best Buy (BBY) downgraded to Equal Weight at Morgan Stanley... CDK Global (CDK) downgraded to Underweight from Equal Weight at Morgan Stanley... Chesapeake Lodging (CHSP) downgraded to Sell from Neutral at Ladenburg... Citrix (CTXS) downgraded to Underweight from Equal Weight at Morgan Stanley... Comstock Resources (CRK) downgraded to Hold from Accumulate at KLR Group... Cypress Energy (CELP) downgraded to Hold from Buy at Stifel... Dunkin' Brands (DNKN) downgraded to Market Perform from Outperform at William Blair... Eleven Biotherapeutics (EBIO) downgraded to Market Perform from Outperform at Leerink... Equity Residential (EQR) downgraded on valuation, rental markets at JMP Securities... Express Scripts (ESRX) downgraded to Market Perform from Outperform at Leerink... LaSalle Hotel (LHO) downgraded to Sell from Neutral at Ladenburg... MSG Networks (MSGN) downgraded to Sell from Hold at Stifel... Madison Square Garden (MSG) downgraded on valuation at Stifel... McCormick (MKC) downgraded to Underweight from Neutral at JPMorgan... Methanex (MEOH) downgraded to Neutral from Buy at Monness Crespi... Nuverra Environmental (NES) downgraded to Hold from Buy at Stifel... OGE Energy (OGE) downgraded to Hold from Buy at Tudor Pickering... Party City (PRTY) downgraded to Equal Weight at Morgan Stanley... Pebblebrook Hotel (PEB) downgraded to Sell from Neutral at Ladenburg... Progressive (PGR) downgraded to Market Perform from Outperform at Bernstein... RLJ Lodging Trust (RLJ) downgraded to Sell from Neutral at Ladenburg... ResMed (RMD) downgraded to Underweight from Equal Weight at Barclays... Rex Energy (REXX) downgraded to Hold from Buy at KLR Group... SM Energy (SM) downgraded to Equalweight from Overweight at Capital One... Sally Beauty (SBH) downgraded to Equal Weight at Morgan Stanley... Santander Brasil (BSBR) downgraded to Reduce from Hold at HSBC... Sarepta (SRPT) downgraded to Sector Perform from Outperform at RBC Capital... Smith & Nephew (SNN) downgraded to Hold from Buy at Deutsche Bank... Sotherly Hotels (SOHO) downgraded to Sell from Buy at Ladenburg... Southwestern Energy (SWN) downgraded to Equalweight from Overweight at Capital One... St. Jude Medical (STJ) downgraded to Market Perform from Outperform at Wells Fargo... Stone Energy (SGY) downgraded to Underweight from Equalweight at Capital One... TerraForm Power (TERP) downgraded to Neutral from Buy at BofA/Merrill... Timken (TKR) downgraded to Hold from Buy at BB&T... Triangle Petroleum (TPLM) downgraded to Hold from Buy at KLR Group... UDR, Inc. (UDR) downgraded at JMP Securities... W&T Offshore (WTI) downgraded to Underweight from Equalweight at Capital One... WPX Energy (WPX) downgraded to Equalweight from Overweight at Capital One... Whiting Petroleum (WLL) downgraded to Equalweight from Overweight at Capital One.

Oppenheimer lowered the firm's price target on ResMed to $200 from $205 and keeps an Outperform rating on the shares. ResMed's Q3 earnings were in line with estimates, and the firm awaits the full SURMOUNT-OSA data readout at ADA in late June, the analyst tells investors in a research note.

KeyBanc raised the firm's price target on ResMed to $238 from $227 and keeps an Overweight rating on the shares. KeyBanc was incrementally encouraged by broad outperformance in Q3, especially given difficult year over year comps in Devices as well as near-term concerns around the potential impacts of GLP-1s, the analyst tells investors in a research note.

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Reports Q3 revenue $1.2B, consensus $1.17B. "ResMed's strong third-quarter fiscal year 2024 results reflect robust patient and customer demand for our products and software solutions, leading to double-digit mask and accessories revenue growth along with ongoing operational efficiencies to drive margin improvement and increased profitability, resulting in double-digit growth in both operating profit and earnings per share," said Mick Farrell, ResMed's Chairman & CEO. "Over 2 billion people worldwide can benefit from a ResMed solution to help them sleep better, breathe better, and receive best-in-class healthcare right where they live. We remain laser-focused on bringing market-leading innovation to customers, including our latest AirCurve11 range of non-invasive ventilators and our recently launched AirFit F40 mask system, combined with our entire portfolio of products, software, and solutions, allowing us to continue to deliver value for all our stakeholders."

BTIG notes that seven Medicare Administrative Contractors, or MACs - CGS, WPS, NGS, Palmetto, Novitas, First Coast, and Noridian - this morning published new proposed local coverage determinations, or LCDs, regarding the coverage of skin substitutes grafts and cellular and tissue based products for the treatment of diabetic foot ulcers, or DFUs, and venous leg ulcers, or VLUs. This marks "the second attempt in the past 12 months where MACs have proposed an LCD that would drastically shake up the advanced wound care market," says the analyst, who highlights that the proposed LCD includes non-coverage products from Integra Lifesciences (IART), Organogenesis (ORGO), Smith & Nephew (SNN), MiMedx (MDXG), Anika Therapeutics (ANIK) and numerous smaller, private wound care companies. The firm adds that it thinks Integra and Organogenesis both have meaningful exposure to the LCDs based on their product portfolio and the revenue mix within their Advanced Wound Care businesses.